Additionally, targeting the receptor tyrosine kinases, c-kit, and PDGFR, with the inhibitor imatinib (Gleevec), provided a long-term benefit to a third of patients suffering from the most aggressive KS subtype, AIDS-KS (Koon et al., 2014). The gene discussed is KIT; the disease is Kaposi's sarcoma.